<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997165</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-Promoteur 08-01</org_study_id>
    <nct_id>NCT00997165</nct_id>
  </id_info>
  <brief_title>Impact of Adipose Tissue Repartition on the Time Course of Vascular Dysfunction - the NUMEVOX Cohort</brief_title>
  <acronym>NUMEVOX</acronym>
  <official_title>Impact of Adipose Tissue Repartition on the Time Course of Vascular Dysfunction - the NUMEVOX Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The NUMEVOX cohort is intended to follow-up the macro and microvascular dysfunction in
      relation to adipose tissue repartition in patients with metabolic syndrome associated to
      liver steatosis, sleep apnea. Duration of the follow-up is 3 years for each patient entering
      the cohort.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Metabolic Diseases</condition>
  <condition>Sleep Apnea</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Metabolic syndrome (MS)</arm_group_label>
    <description>Patients suspected of metabolic syndrome without sleep apnea or liver steatosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MS with sleep apnea</arm_group_label>
    <description>Metabolic syndrome with sleep apnea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MS with Liver steatosis</arm_group_label>
    <description>Metabolic syndrome with liver steatosis</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum and DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient suspected of metabolic syndrome with or without sleep apnea or liver steatosis.

        Informed consent with signature.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent

          -  age &gt; 18 years old

          -  suspected of metabolic syndrome

          -  affiliated to french social health care

        Exclusion Criteria:

          -  age &lt; 18 years old

          -  pregnancy

          -  no informed consent

          -  not eligible for the study (no MS, cancer)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>pierre henri Ducluzeau, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>UH Angers</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>PIERRE HENRI DUCLUZEAU, MD PhD</last_name>
    <phone>33(0)663384160</phone>
    <email>phducluzeau@chu-angers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>GEORGES LEFTHERIOTIS, MD-PHD</last_name>
    <phone>33(2)41-35-44-56</phone>
    <email>geleftheriotis@chu-angers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pôle Maladies Métaboliques et Médecine Interne</name>
      <address>
        <city>Angers</city>
        <zip>49993</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>GEORGES LEFTHERIOTIS, MD-PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>FREDERIC GAGNADOUX, MD-PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>PAUL CALES, MD-PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2009</study_first_submitted>
  <study_first_submitted_qc>October 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2009</study_first_posted>
  <last_update_submitted>October 16, 2009</last_update_submitted>
  <last_update_submitted_qc>October 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Pierre Henri Ducluzeau/MD-PhD</name_title>
    <organization>UH Angers</organization>
  </responsible_party>
  <keyword>fatty liver</keyword>
  <keyword>adipose tissue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

